Reported Earlier, Medicenna Therapeutics Doses First Patient In Phase 2 Monotherapy Dose Expansion Portion Of The ABILITY Study Evaluating MDNA11 In Select Types Of Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Medicenna Therapeutics has dosed the first patient in the Phase 2 monotherapy dose expansion portion of the ABILITY study evaluating MDNA11 in select types of solid tumors. The company expects to report initial results from both the monotherapy and combination arms of the Phase 2 dose expansion study in H1 2024. The combination arm of the trial evaluating MDNA11 with pembrolizumab is expected to commence by the end of this year.
October 25, 2023 | 7:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medicenna Therapeutics has begun Phase 2 of the ABILITY study evaluating MDNA11. This could potentially lead to a new treatment for solid tumors, which would be a significant development for the company.
The commencement of Phase 2 of the ABILITY study is a significant milestone for Medicenna Therapeutics. If the study is successful, it could lead to a new treatment for solid tumors, which would be a major development for the company and could potentially boost its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100